Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026

On November 19, 2026 Bristol Myers Squibb (NYSE: BMY) reported it will present new data from its robust hematology portfolio through more than 90 company- and partner-sponsored disclosures, including 24 oral presentations, at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, taking place in New Orleans, Louisiana, from December 12-15, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This has been an extraordinary year across our blood cancer portfolio, and what we’re sharing at ASH (Free ASH Whitepaper) is the realization of our scientific investments," said Cristian Massacesi, MD, executive vice president, chief medical officer and head of development, Bristol Myers Squibb. "At ASH (Free ASH Whitepaper), we’re highlighting the breadth of our work in blood cancers from Phase 3 CELMoD datasets in multiple myeloma, exploration of targeted protein degradation’s potential in follicular lymphoma, five-year landmark survival data for Breyanzi and the clinical potential of our dual-targeted CAR T, tunlucabtagene autoleucel. Together, these advancements reflect one goal: to move beyond the current standard management of blood cancers and redefine what patients can expect from treatment."

Data presented by Bristol Myers Squibb will underscore both the strength of the Company’s commercial portfolio and the rapid momentum of its innovative early- and late-stage pipeline in targeted protein degradation, including CELMoDs and other protein degradation approaches, alongside next-generation autologous CAR T cell therapy.

Key data being presented at ASH (Free ASH Whitepaper) by Bristol Myers Squibb and its collaborators include:

Evolving multiple myeloma through powerful CELMoD combinations and next-generation cell therapies

Phase 3 EXCALIBER-RRMM progression-free survival (PFS) and minimal residual disease results for ZENBEXUS, daratumumab, and dexamethasone versus daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma (RRMM), to be featured in oral presentation
Phase 1 safety and efficacy results for dual-targeting BCMA×GPRC5D autologous CAR T cell therapy tunlucabtagene autoleucel (tunlu-cel; BMS-986453) in patients with RRMM, to be featured in oral presentation
PFS results and outcomes by prior exposure to pomalidomide or T-cell-redirecting therapy from the SUCCESSOR-2 study evaluating mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone (Kd) in patients with RRMM
Phase 1 arlocabtagene autoleucel (arlo-cel) oral presentation on GPRC5D expression and locus integrity in patients with RRMM
Initial Phase 1 results evaluating mezigdomide in combination with elranatamab for the treatment of RRMM
Advancing lymphoma care with targeted protein degradation and curative intent

Phase 2 GOLSEEK-2 results for golcadomide, an investigational oral CELMoD agent, plus rituximab in patients with newly-diagnosed advanced-stage follicular lymphoma, to be featured in oral presentation
Landmark five-year follow-up from the pivotal Phase 3 TRANSFORM study demonstrating the curative potential of Breyanzi in second-line (2L) relapsed or refractory large B-cell lymphoma (LBCL)
Evaluation of real-world effectiveness and safety outcomes for Breyanzi versus bispecific antibodies in 2L LBCL
Delivering disease breadth and leadership in myeloid disorders

Phase 2 results for Reblozyl (luspatercept-aamt) in adults with non-transfusion-dependent (NTD) α-thalassemia hemoglobin H (HbH) disease, to be featured in oral presentation
Phase 2a results for Reblozyl in adolescents with transfusion-dependent (TD) β-thalassemia, to be featured in oral presentation
Details on key presentations at the 2026 ASH (Free ASH Whitepaper) Annual Meeting are available below, with full abstracts available through the congress online program.

Abstract Title

Author

Presentation Type/Abstract #

Session Title

Date/Time (CST)

Multiple Myeloma

BMS-986453, a dual-targeting BCMA×GPRC5D autologous CAR T cell therapy with polyfunctional phenotype: A first-in-human study in patients with relapsed/refractory multiple myeloma

Sidana, S.

Oral

#116

655. Multiple Myeloma: Cellular Therapies: CAR T in Myeloma: Racing Towards a Cure

Saturday, December 12

9:45-10 AM

Progression-free survival (PFS) and minimal residual disease (MRD) outcomes with iberdomide, daratumumab and dexamethasone (IberDd) versus daratumumab, bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 EXCALIBER-RRMM study

Lonial, S.

Oral

#114

654. Multiple Myeloma: Pharmacologic Therapies

Saturday, December 12

10:45-11 AM

GPRC5D expression and locus integrity in relapsed/refractory multiple myeloma treated with arlocabtagene autoleucel in a first-in-human phase 1 trial

Ziyad, S.

Oral

#120

655. Multiple Myeloma: Cellular Therapies: CAR T in Myeloma: Racing Towards a Cure

Saturday, December 12

10:45-11 AM

Characterization and management of adverse events of clinical relevance with iberdomide, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma from the phase 3 EXCALIBER-RRMM trial

Quach, H.

Poster

#2255

Poster Session I

Saturday, December 12

5:30-7:30 PM

Cumulative treatment-altering toxicities in patients with relapsed/refractory multiple myeloma treated with bispecific antibodies

Hansen, D.

Poster

#2228

Poster Session I

Saturday, December 12

5:30-7:30 PM

Collab-led CDC: Elranatamab plus iberdomide in patients with relapsed or refractory multiple myeloma: Dose escalation results from the MagnetisMM-30 trial

Lesokhin, A.

Poster

#2265

Poster Session I

Saturday, December 12

5:30-7:30 PM

Mezigdomide adds a multi-lineage activation and effector-differentiation program to BCMA T-cell engager therapy: Bone marrow and peripheral blood immune pharmacodynamics of elranatamab plus mezigdomide in relapsed/refractory multiple myeloma

Jeyaraju, D.

Poster

#2162

Poster Session I

Saturday, December 12

5:30-7:30 PM

SUCCESSOR-2 update: Progression-free survival and outcomes by prior exposure to pomalidomide or T-cell-redirecting therapy with mezigdomide, carfilzomib, and dexamethasone versus Kd in relapsed/refractory multiple myeloma

Schjesvold, F.

Poster

#4012

Poster Session II

Sunday, December 13

6-8 PM

Mezigdomide in combination with elranatamab for the treatment of relapsed/refractory multiple myeloma: Initial phase 1 results from a phase 1b/2a trial

Costa, L.

Poster

#4009

Poster Session II

Sunday, December 13

6-8 PM

ESR-CRC: Teclistmamab and mezigdomide for relapsed/refractory multiple myeloma, the MATRIX phase 1b trial

Hultcrantz, M.

Poster

#4026

Poster Session II

Sunday, December 13

6-8 PM

SUCCESSOR-2 dose optimization: Stage 1 analysis of mezigdomide starting dose in combination with carfilzomib and dexamethasone for relapsed/refractory multiple myeloma

Alkharabsheh, O.

Poster

#5775

Poster Session III

Monday, December 14

6-8 PM

Matching-adjusted indirect comparisons of iberdomide + daratumumab + dexamethasone versus daratumumab + carfilzomib + dexamethasone and isatuximab + carfilzomib + dexamethasone in RRMM

Landgren, O.

Poster

#5784

Poster Session III

Monday, December 14

6-8 PM

Arlocabtagene autoleucel in patients with heavily pretreated relapsed/refractory multiple myeloma: Analysis of on-target, off-tumor safety
Berdeja, J.

Poster

#5938
Poster Session III

Monday, December 14

6-8 PM
Lymphoma

Phase 2 trial of obinutuzumab and golcadomide for patients with previously untreated high tumor burden follicular lymphoma

Chihara, D.

Oral

#164

623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological – Is Chemo-immunotherapy Ready for Retirement? Bispecific and CELMoD-Based Frontline Regimens in Follicular Lymphoma

Saturday, December 12

12:15-12:30 PM

Golcadomide, a potential, first-in-class, oral CELMoD plus rituximab in patients with newly diagnosed, advanced-stage follicular lymphoma: Safety and 12-month efficacy from the phase 2 GOLSEEK-2 study

Villasboas, J.

Oral

#165

623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological – Is Chemo-immunotherapy Ready for Retirement? Bispecific and CELMoD-Based Frontline Regimens in Follicular Lymphoma

Saturday, December 12

12:30-12:45 PM

Evaluation of real-world effectiveness and safety outcomes for lisocabtagene maraleucel and bispecific antibodies in second-line relapsed or refractory large B-cell lymphoma

Epperla, N.

Oral

#315

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders – Beyond Response: Toxicity, Infection, and Late Events After Novel Therapies

Saturday, December 12

2:30-2:45 PM

Golcadomide, a potential, first-in-class, oral CELMoD + Pola-R-CHP in patients with newly diagnosed aggressive B-cell lymphoma: Safety and 24-month efficacy from a phase 1b study

Hoffman, M.

Poster

#1885

Poster Session I

Saturday, December 12

5:30-7:30 PM

Bulky disease and/or elevated LDH identify a high-risk subgroup in international prognostic index 1–2 newly diagnosed large B-cell lymphoma: Evidence from the LEO and REALYSA cohorts

Maurer, M.

Oral

#520

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Evaluation of Newly-Diagnosed DLBCL Patients

Sunday, December 13

10:15-10:30 AM

BMS-986458, a first-in-class degrader of B-cell lymphoma 6 in patients with relapsed/refractory follicular lymphoma: Updated safety and efficacy of BMS-986458 monotherapy in a phase 1/2 study

Van Der Poel, M.

Poster

#3549

Poster Session II

Sunday, December 13

6-8 PM

Lisocabtagene maraleucel versus standard of care for second-line relapsed or refractory large B-cell lymphoma: 5-y follow-up results from TRANSFORM

Abramson, J.

Poster

#3682

Poster Session II

Sunday, December 13

6-8 PM

Clinical efficacy and longitudinal safety of lisocabtagene maraleucel in patients with third-line or later follicular lymphoma: 4-y update from the phase 2 TRANSCEND FL study

Kamdar, M.

Poster

#3577

Poster Session II

Sunday, December 13

6-8 PM

Myeloid

Luspatercept in adults with non-transfusion-dependent α-thalassemia hemoglobin H disease: Primary efficacy and safety data from a phase 2, double-blind, randomized, placebo-controlled, multicenter trial

Viprakasit, V.

Oral

#7

112. Thalassemia and Globin Gene Regulation: Advances Across the Thalassemia Spectrum: Novel Targets and Therapeutics

Saturday, December 12

9:30-9:45 AM

Luspatercept in adolescent patients with transfusion-dependent β thalassemia: Efficacy and safety results from a phase 2a trial

Viprakasit, V.

Oral

#12

112. Thalassemia and Globin Gene Regulation: Advances Across the Thalassemia Spectrum: Novel Targets and Therapeutics

Saturday, December 12

10:45-11 AM

Effectiveness of early first-line luspatercept use in patients with lower-risk myelodysplastic syndromes: A real-world analysis from Florida Cancer Specialists & Research Institute

Fonseca, G.

Poster

#2669

Poster Session I

Saturday, December 12

5:30-7:30 PM

Efficacy of luspatercept by baseline anemia burden in patients with myelofibrosis: Subgroup analyses from the phase 3 INDEPENDENCE trial

Al-Ali, H.

Poster

#2001

Poster Session I

Saturday, December 12

5:30-7:30 PM

Luspatercept in adults with transfusion-dependent α-thalassemia hemoglobin H disease: Primary efficacy and safety data from a phase 2, double-blind, randomized, placebo-controlled, multicenter trial

Kattamis, A.

Poster

#2899

Poster Session II

Sunday, December 13

6-8 PM

Anemia management and survival outcomes among previously treated patients with myelofibrosis receiving luspatercept: A real-world analysis

Hobbs, G.

Poster

#6359

Poster Session III

Monday, December 14

6-8 PM

BREYANZI
INDICATIONS
BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:

adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:
refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or
refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or
relapsed or refractory disease after two or more lines of systemic therapy.
adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
adult patients with relapsed or refractory follicular lymphoma (FL) who have received 2 or more prior lines of systemic therapy.
adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor.
adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least 2 prior lines of systemic therapy.
Important Safety Information

WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, AND SECONDARY HEMATOLOGICAL MALIGNANCIES

Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving BREYANZI. Do not administer BREYANZI to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab with or without corticosteroids.
Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving BREYANZI, including concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with BREYANZI. Provide supportive care and/or corticosteroids as needed.
T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including BREYANZI.
Cytokine Release Syndrome

Cytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred following treatment with BREYANZI. In clinical trials of BREYANZI, which enrolled a total of 769 patients with non-Hodgkin lymphoma (NHL), CRS occurred in 56% of patients, including ≥ Grade 3 CRS in 3.4% of patients. The median time to onset was 5 days (range: 1 to 63 days). CRS resolved in 99% of patients with a median duration of 5 days (range: 1 to 37 days). One patient had fatal CRS and 5 patients had ongoing CRS at the time of death. The most common manifestations of CRS (≥10%) were fever, hypotension, chills, tachycardia, hypoxia, and headache.

Serious events that may be associated with CRS include cardiac arrhythmias (including atrial fibrillation and ventricular tachycardia), cardiac arrest, cardiac failure, diffuse alveolar damage, renal insufficiency, capillary leak syndrome, hypotension, hypoxia, and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).

Ensure that 2 doses of tocilizumab are available prior to infusion of BREYANZI.

Neurologic Toxicities

Neurologic toxicities that were fatal or life-threatening, including immune effector cell-associated neurotoxicity syndrome (ICANS), occurred following treatment with BREYANZI. Serious events including cerebral edema and seizures occurred with BREYANZI. Fatal and serious cases of leukoencephalopathy, some attributable to fludarabine, also occurred.

In clinical trials of BREYANZI (excluding primary central nervous system lymphoma), CAR T cell-associated neurologic toxicities occurred in 32% of patients, including ≥ Grade 3 cases in 10% of patients. The median time to onset of neurotoxicity was 8 days (range: 1 to 63 days). Neurologic toxicities resolved in 88% of patients with a median duration of 7.5 days (range: 1 to 119 days). Of patients developing neurotoxicity, 83% also developed CRS. The most common neurologic toxicities (≥5%) included encephalopathy, tremor, aphasia, delirium, and headache.

In Study 6, neurologic toxicities occurred in 40% (2/5) of patients with relapsed or refractory primary central nervous system lymphoma (PCNSL). The time to onset of neurologic toxicities ranged from 3 to 8 days and duration ranged from 7 to 22 days. Neurologic toxicities included seizure (20%), headache (20%), encephalopathy (20%), and paresis (20%).

CRS and Neurologic Toxicities Monitoring

Monitor patients daily for at least 7 days following BREYANZI infusion for signs and symptoms of CRS and neurologic toxicities and assess for other causes of neurological symptoms. Continue to monitor patients for signs and symptoms of CRS and neurologic toxicities for at least 2 weeks after infusion and treat promptly. At the first sign of CRS, institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids as indicated. Manage neurologic toxicity with supportive care and/or corticosteroid as needed. Advise patients to avoid driving for at least 2 weeks following infusion. Counsel patients to seek immediate medical attention should signs or symptoms of CRS or neurologic toxicity occur at any time.

Hypersensitivity Reactions

Allergic reactions may occur with the infusion of BREYANZI. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide (DMSO).

Serious Infections

Severe infections, including life-threatening or fatal infections, have occurred in patients after BREYANZI infusion. In clinical trials of BREYANZI, infections of any grade occurred in 33% of patients, with Grade 3 or higher infections occurring in 12% of all patients. Grade 3 or higher infections with an unspecified pathogen occurred in 7%, bacterial infections in 3.5%, viral infections in 2%, and fungal infections in 0.7% of patients. One patient who received 4 prior lines of therapy developed a fatal case of John Cunningham (JC) virus progressive multifocal leukoencephalopathy 4 months after treatment with BREYANZI. One patient who received 3 prior lines of therapy developed a fatal case of cryptococcal meningoencephalitis 35 days after treatment with BREYANZI.

Febrile neutropenia developed after BREYANZI infusion in 8% of patients. Febrile neutropenia may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated.

Monitor patients for signs and symptoms of infection before and after BREYANZI administration and treat appropriately. Administer prophylactic antimicrobials according to standard institutional guidelines. Avoid administration of BREYANZI in patients with clinically significant, active systemic infections.

Viral reactivation: Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells. In clinical trials of BREYANZI, 35 of 38 patients with a prior history of HBV were treated with concurrent antiviral suppressive therapy. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing. In patients with prior history of HBV, consider concurrent antiviral suppressive therapy to prevent HBV reactivation per standard guidelines.

Prolonged Cytopenias

Patients may exhibit cytopenias not resolved for several weeks following lymphodepleting chemotherapy and BREYANZI infusion. In clinical trials of BREYANZI, Grade 3 or higher cytopenias persisted at Day 29 following BREYANZI infusion in 35% of patients, and included thrombocytopenia in 25%, neutropenia in 22%, and anemia in 6% of patients. Monitor complete blood counts prior to and after BREYANZI administration.

Hypogammaglobulinemia

B-cell aplasia and hypogammaglobulinemia can occur in patients receiving BREYANZI. In clinical trials of BREYANZI, hypogammaglobulinemia was reported as an adverse reaction in 9% of patients. Hypogammaglobulinemia, either as an adverse reaction or laboratory IgG level below 500 mg/dL after infusion, was reported in 30% of patients. Monitor immunoglobulin levels after treatment with BREYANZI and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement as clinically indicated.

Live vaccines: The safety of immunization with live viral vaccines during or following BREYANZI treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during BREYANZI treatment, and until immune recovery following treatment with BREYANZI.

Secondary Malignancies

Patients treated with BREYANZI may develop secondary malignancies. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including BREYANZI. Mature T cell malignancies, including CAR-positive tumors, may present as soon as weeks following infusion, and may include fatal outcomes. Monitor lifelong for secondary malignancies. In the event that a secondary malignancy occurs, contact Bristol-Myers Squibb at 1-888-805-4555 for reporting and to obtain instructions on collection of patient samples for testing.

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS)

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS), including fatal or life-threatening reactions, occurred following treatment with BREYANZI. Seven out of 769 (0.9%) patients with R/R NHL exposed to BREYANZI developed IEC-HS. Time to onset of IEC-HS ranged from 7 to 32 days. Of the 7 patients, 3 patients developed IEC-HS with overlapping occurrence of CRS and neurotoxicity, 2 patients developed IEC-HS with overlapping occurrence of neurotoxicity, and 1 patient developed IEC-HS with overlapping occurrence of CRS. IEC-HS was fatal in 2 of 7 patients. One patient had fatal IEC-HS and one had ongoing IEC-HS at time of death. IEC-HS is a life-threatening condition with a high mortality rate if not recognized and treated early. Treatment of IEC-HS should be administered per current practice guidelines.

Adverse Reactions

The most common adverse reaction(s) (incidence ≥30%) in:

LBCL are fever, CRS, fatigue, musculoskeletal pain, and nausea. The most common Grade 3-4 laboratory abnormalities include lymphocyte count decrease, neutrophil count decrease, platelet count decrease, and hemoglobin decrease.
CLL/SLL are CRS, encephalopathy, fatigue, musculoskeletal pain, nausea, edema, and diarrhea. The most common Grade 3-4 laboratory abnormalities include neutrophil count decrease, white blood cell decrease, hemoglobin decrease, platelet count decrease, and lymphocyte count decrease.
FL is CRS. The most common Grade 3-4 laboratory abnormalities include lymphocyte count decrease, neutrophil count decrease, and white blood cell decrease.
MCL are CRS, fatigue, musculoskeletal pain, and encephalopathy. The most common Grade 3-4 laboratory abnormalities include neutrophil count decrease, white blood cell decrease, and platelet count decrease.
MZL is CRS. The most common Grade 3-4 laboratory abnormalities include lymphocyte count decrease, neutrophil count decrease, and white blood cell decrease.
Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide.

REBLOZYL
REBLOZYL (luspatercept-aamt) is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

REBLOZYL (luspatercept-aamt) is indicated for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.

REBLOZYL (luspatercept-aamt) is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombosis/Thromboembolism

In adult patients with beta thalassemia, thromboembolic events (TEE) were reported in 8/223 (3.6%) of REBLOZYL-treated patients. TEEs included deep vein thrombosis, pulmonary embolus, portal vein thrombosis, and ischemic stroke. Patients with known risk factors for thromboembolism (splenectomy or concomitant use of hormone replacement therapy) may be at further increased risk of thromboembolic conditions. Consider thromboprophylaxis in patients at increased risk of TEE. Monitor patients for signs and symptoms of thromboembolic events and institute treatment promptly.

Hypertension

Hypertension was reported in 11.4% (63/554) of REBLOZYL-treated patients. Across clinical studies, the incidence of Grade 3 to 4 hypertension ranged from 2% to 9.6%. In patients with beta thalassemia with normal baseline blood pressure, 13 (6.2%) patients developed systolic blood pressure (SBP) ≥130 mm Hg and 33 (16.6%) patients developed diastolic blood pressure (DBP) ≥80 mm Hg. In ESA-refractory or -intolerant adult patients with MDS with normal baseline blood pressure, 26 (30%) patients developed SBP ≥130 mm Hg and 23 (16%) patients developed DBP ≥80 mm Hg. In ESA-naïve adult patients with MDS with normal baseline blood pressure, 23 (36%) patients developed SBP ≥140 mm Hg and 11 (6%) patients developed DBP ≥80 mm Hg. Monitor blood pressure prior to each administration. Manage new or exacerbations of preexisting hypertension using anti-hypertensive agents.

Extramedullary Hematopoietic (EMH) Masses

In adult patients with transfusion-dependent beta thalassemia, EMH masses were observed in 3.2% of REBLOZYL-treated patients, with spinal cord compression symptoms due to EMH masses occurring in 1.9% of patients (BELIEVE and REBLOZYL long-term follow-up study).

In a study of adult patients with non-transfusion-dependent beta thalassemia, a higher incidence of EMH masses was observed in 6.3% of REBLOZYL-treated patients vs. 2% of placebo-treated patients in the double-blind phase of the study, with spinal cord compression due to EMH masses occurring in 1 patient with a prior history of EMH. REBLOZYL is not indicated for use in patients with non-transfusion-dependent beta thalassemia.

Possible risk factors for the development of EMH masses in patients with beta thalassemia include history of EMH masses, splenectomy, splenomegaly, hepatomegaly, or low baseline hemoglobin (<8.5 g/dL). Signs and symptoms may vary depending on the anatomical location. Monitor patients with beta thalassemia at initiation and during treatment for symptoms and signs or complications resulting from the EMH masses and treat according to clinical guidelines. Discontinue treatment with REBLOZYL in case of serious complications due to EMH masses. Avoid use of REBLOZYL in patients requiring treatment to control the growth of EMH masses.

Embryo-Fetal Toxicity

REBLOZYL may cause fetal harm when administered to a pregnant woman. REBLOZYL caused increased post-implantation loss, decreased litter size, and an increased incidence of skeletal variations in pregnant rat and rabbit studies. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 3 months after the final dose.

ADVERSE REACTIONS

Beta-Thalassemia

Serious adverse reactions occurred in 3.6% of patients on REBLOZYL. Serious adverse reactions occurring in 1% of patients included cerebrovascular accident and deep vein thrombosis. A fatal adverse reaction occurred in 1 patient treated with REBLOZYL who died due to an unconfirmed case of acute myeloid leukemia (AML).

Most common adverse reactions (at least 10% for REBLOZYL and 1% more than placebo) were headache (26% vs 24%), bone pain (20% vs 8%), arthralgia (19% vs 12%), fatigue (14% vs 13%), cough (14% vs 11%), abdominal pain (14% vs 12%), diarrhea (12% vs 10%) and dizziness (11% vs 5%).

ESA-naïve adult patients with Myelodysplastic Syndromes

Grade >3 (>2%) adverse reactions included hypertension and dyspnea.

The most common (>10%) all-grade adverse reactions included diarrhea, fatigue, hypertension, peripheral edema, nausea, and dyspnea.

ESA-refractory or -intolerant adult patients with Myelodysplastic Syndromes

Grade ≥3 (≥2%) adverse reactions included fatigue, hypertension, syncope and musculoskeletal pain. A fatal adverse reaction occurred in 5 (2.1%) patients.

The most common (≥10%) adverse reactions included fatigue, musculoskeletal pain, dizziness, diarrhea, nausea, hypersensitivity reactions, hypertension, headache, upper respiratory tract infection, bronchitis, and urinary tract infection.

LACTATION

It is not known whether REBLOZYL is excreted into human milk or absorbed systemically after ingestion by a nursing infant. REBLOZYL was detected in milk of lactating rats. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because many drugs are excreted in human milk, and because of the unknown effects of REBLOZYL in infants, a decision should be made whether to discontinue nursing or to discontinue treatment. Because of the potential for serious adverse reactions in the breastfed child, breastfeeding is not recommended during treatment and for 3 months after the last dose.

DRUG ABUSE POTENTIAL

Abuse: Abuse of REBLOZYL may be seen in athletes for the effects on erythropoiesis. Misuse of drugs that increase erythropoiesis, such as REBLOZYL, by healthy persons may lead to polycythemia, which may be associated with life-threatening cardiovascular complications.

Please see U.S. Full Prescribing Information for REBLOZYL.

ZENBEXUS
ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

WARNING: EMBRYO-FETAL TOXICITY and SERIOUS VENOUS AND ARTERIAL THROMBOEMBOLISM

EMBRYO-FETAL TOXICITY

ZENBEXUS is contraindicated in pregnancy. ZENBEXUS is embryo-fetal toxic in animals and can cause birth defects or embryo-fetal death in humans. In females of reproductive potential, obtain 2 negative pregnancy tests before starting ZENBEXUS treatment.

Females of reproductive potential must use 2 effective forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after last dose of ZENBEXUS treatment.

Because of the risk of embryo-fetal toxicity, ZENBEXUS is only available through a restricted distribution program called ZENBEXUS REMS.

SERIOUS VENOUS AND ARTERIAL THROMBOEMBOLISM

Increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke in patients with multiple myeloma receiving ZENBEXUS with daratumumab and hyaluronidase-fihj and dexamethasone. Anti-thrombotic prophylaxis is recommended.

CONTRAINDICATIONS

Based on the mechanism of action and findings in animal studies, ZENBEXUS can cause birth defects or embryo-fetal death in humans. ZENBEXUS is contraindicated in females who are pregnant. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be informed of the potential hazard to a fetus.

WARNINGS AND PRECAUTIONS

Embryo-Fetal Toxicity

Females of Reproductive Potential: Must avoid pregnancy while taking ZENBEXUS and for at least 4 weeks after completing therapy. Advise females of reproductive potential of the potential risk to a fetus and to use 2 methods of effective contraception for at least 4 weeks before beginning ZENBEXUS therapy, during therapy, during dose interruptions and for at least 4 weeks after the last dose of ZENBEXUS therapy. Refer patients who can become pregnant to a qualified provider of contraceptive methods, if needed.

Two negative pregnancy tests with a sensitivity of at least 25 mIU/mL must be obtained prior to initiating therapy. Pregnancy testing should be performed weekly during the first 4 weeks of treatment. Thereafter, testing should occur every 4 weeks in patients with regular menstrual cycles, or every 2 weeks in patients with irregular menstrual cycles.

Females of reproductive potential taking ZENBEXUS must not donate eggs during treatment and for 4 weeks after completion.

Males: ZENBEXUS may pass into human semen. Advise patients who can impregnate partners to use effective contraception during treatment and for 4 weeks following the discontinuation of ZENBEXUS therapy. Male patients taking ZENBEXUS must not donate sperm during treatment and for 4 weeks after completion.

Blood Donation: Patients must not donate blood during treatment with ZENBEXUS and for 4 weeks following discontinuation of ZENBEXUS therapy.

ZENBEXUS REMS

ZENBEXUS is available only through a restricted program called ZENBEXUS REMS, because of the risk of embryo-fetal toxicity. Prescribers must be certified with and patients must be enrolled in the ZENBEXUS REMS Program and comply with ongoing monitoring and contraception requirements. Further information about ZENBEXUS REMS, including information for pharmacies, wholesalers, and distributors, is available at www.ZENBEXUSREMS.com or by telephone at 1-888-423-5436.

Serious Venous and Arterial Thromboembolism

ZENBEXUS can cause serious and life-threatening venous thromboembolic events (DVT and PE) and arterial thromboembolic events (myocardial infarction and stroke). In the EXCALIBER-RRMM study (N=204), venous thromboembolic events occurred in 6.4% of patients treated with ZENBEXUS combined with daratumumab and hyaluronidase-fihj and dexamethasone (IberDd) despite mandatory thromboembolism prophylaxis. The incidence of DVT was 3.4% and the incidence of PE was 1.5%.

Arterial thromboembolic events occurred in 3.4% of patients. The incidence of myocardial infarction was 2.0%, and the incidence of stroke (CVA) was 1.5%.

Monitor patients for signs and symptoms of thromboembolic events during treatment with ZENBEXUS. Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient’s underlying risk factors. In patients who develop a thromboembolism, interrupt ZENBEXUS and initiate anticoagulant therapy according to guidelines.

Neutropenia

ZENBEXUS can cause severe neutropenia. In the EXCALIBER-RRMM study, all-grade neutropenia was reported in 90.2%, Grade 3 in 30.9%, and Grade 4 in 53.4% of patients in the IberDd arm. Febrile neutropenia occurred in 5.4% of patients.

Monitor complete blood count throughout treatment with ZENBEXUS. Interrupt, reduce dosage, or discontinue ZENBEXUS, as necessary. Initiate granulocyte colony-stimulating factor (GCSF) as appropriate per guidelines.

Infections

ZENBEXUS can cause serious infections, including life-threatening or fatal infections. Patients with active or uncontrolled infection should not start ZENBEXUS treatment until the infection is controlled. In the EXCALIBER-RRMM study, infections, including opportunistic infections, were reported in 78.9%, Grade 3 in 35.8%, Grade 4 in 3.4%, and fatal infections in 2% of patients receiving IberDd. Serious infections occurred in 40% of patients. Discontinuations due to infections occurred in 1.5% of patients.

Monitor patients for signs and symptoms of infection prior to and during treatment with ZENBEXUS and treat appropriately. Withhold or reduce the dose based on severity.

Consider prophylactic anti-infective medications according to current practice guidelines.

Second Primary Malignancies

In the EXCALIBER-RRMM study, at a median follow-up time of 16 months, second primary malignancies (SPM) occurred in 6.9% of patients in the IberDd arm and 4.9% of patients in the daratumumab and hyaluronidase-fihj, bortezomib, and dexamethasone (DVd) arm.

Monitor patients for the development of SPM.

ADVERSE REACTIONS

Serious adverse reactions occurred in 58.3% of patients receiving ZENBEXUS. Serious adverse reactions in ≥2% of patients included pneumonia (26%), upper respiratory tract infection (6.4%), SPM (5.9%), neutropenia (4.9%), febrile neutropenia (3.9%), COVID-19 (4.4%), and sepsis (2.9%). Fatal adverse reactions occurred in 10 patients (4.9%) who received ZENBEXUS. Sepsis (1.5%) was the only fatal drug reaction that occurred in more than 1 patient. The following fatal adverse reactions occurred in 1 patient each: listeria encephalitis, influenza, lung adenocarcinoma, cardiac arrest, large intestine perforation, metabolic acidosis, and respiratory failure.

The most common adverse reactions (≥20%) in the IberDd arm and DVd arm, respectively, were upper respiratory tract infection (54% and 52%), fatigue (36% and 33%), musculoskeletal pain (35% and 33%), pneumonia (34% and 17%), diarrhea (33% and 36%), motor dysfunction (26% and 17%), rash (26% and 15%), sleep disorder (25% and 28%), hypogammaglobulinemia (24% and 12%), COVID-19 (23% and 16%), and constipation (20% and 22%).

The most common Grade 3 to 4 laboratory abnormalities (≥30%) in the IberDd arm and DVd arm, respectively, were neutropenia (77% and 11%), leukopenia (69% and 18%), and lymphopenia (62% and 51%).

DRUG INTERACTIONS

Effects of Other Drugs on ZENBEXUS

Strong or Moderate CYP3A Inhibitors: Coadministration of ZENBEXUS with strong or moderate CYP3A inhibitors should be avoided. If a strong or moderate CYP3A inhibitor must be used in combination with ZENBEXUS, reduce the ZENBEXUS dose. Concomitant use with strong or moderate CYP3A inhibitors may increase the risk of adverse reactions.

Strong or Moderate CYP3A Inducers: Coadministration of ZENBEXUS with strong or moderate CYP3A inducers should be avoided. Concomitant use with a strong or moderate CYP3A inducer may decrease the efficacy of ZENBEXUS.

SPECIFIC POPULATIONS

Pregnancy (See the BOXED WARNINGS)

There is a pregnancy exposure registry that monitors outcomes in patients exposed to ZENBEXUS during pregnancy. See the ZENBEXUS REMS WARNINGS AND PRECAUTIONS section.

Lactation

Advise women not to breastfeed during treatment with ZENBEXUS. Refer to the Prescribing Information for daratumumab hyaluronidase-fihj or dexamethasone for additional information.

Females and Males of Reproductive Potential

ZENBEXUS can cause fetal harm when administered during pregnancy.

Pregnancy Testing, Females of Reproductive Potential, and Males: See the Embryo-Fetal Toxicity WARNINGS AND PRECAUTIONS section.

Geriatric Use

In patients treated with IberDd, the incidence of serious adverse reactions was 53%, 56%, and 74% in adult patients younger than 65 years of age, 65 years of age to younger than 75 years of age, and 75 years of age and older, respectively.

Renal Impairment

Reduce the ZENBEXUS dose in patients with estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m2 not on dialysis. If dose modification is needed due to adverse events, reduce the ZENBEXUS dose to 1 mg every other day on Days 1 to 21 of a 28-day cycle.

Please see full Prescribing Information for ZENBEXUS including Boxed WARNINGS.

About Targeted Protein Degradation and CELMoD
Targeted protein degradation (TPD) is a differentiated research platform at Bristol Myers Squibb built on more than two decades of scientific expertise, providing new avenues to degrade therapeutically relevant proteins that were previously considered difficult to address. BMS is the only company that has successfully developed and commercialized protein degrader agents for the treatment of multiple myeloma. These agents, known as immunomodulatory drugs (IMiDs), helped establish the current standard of care in the treatment of this disease, which remains without a cure. BMS is building on this foundation with several investigational protein degraders in clinical trials, leveraging three different modalities including cereblon E3 ligase modulators (CELMoDs), ligand-directed degraders (LDDs), and degrader antibody conjugates (DACs). This three-pronged approach enables matching the right therapeutic modality to a molecular mechanism of action to modulate targets most effectively and ultimately provides more opportunities for potential breakthroughs that may offer meaningful new options for patients across a broad range of diseases, in and beyond hematology and oncology. Learn more about the science behind TPD at Bristol Myers Squibb.

(Press release, Bristol-Myers Squibb, NOV 19, 2026, View Source [SID1234674988])

BioMimetix Announces Publication of Phase I/II Clinical Trial Evaluating BMX-001 in Patients With Locally Advanced Head and Neck Cancer

On November 19, 2026 BioMimetix JV, LLC reported the publication of results from a NCI funded multicenter Phase I/II clinical trial evaluating BMX-001, a redox-active metalloporphyrin compound, in patients undergoing chemoradiation for locally advanced head and neck squamous cell carcinoma (HNSCC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study found that BMX-001 was safe and well tolerated and suggested substantial efficacy in mitigating treatment-related toxicities, including oral mucositis, xerostomia, and radiation dermatitis, in patients who received standard of care chemoradiation.

The results have been published in the International Journal of Radiation Oncology, Biology, Physics.

"The reduction of treatment-related toxicities is a major and elusive challenge in the management of head and neck cancer," said David M. Brizel, MD, Principal Investigator of the study. "These findings suggest that BMX-001 will reduce the severity of these toxicities while maintaining the effectiveness of chemoradiation therapy."

Key Study Findings
This single-arm Phase I/II study enrolled 29 patients with stage III–IV head and neck squamous cell carcinoma who received the investigational drug, BMX-001, in combination with chemoradiation therapy.

Key results included:

Favorable safety profile, with only one patient experiencing serious adverse events possibly related to BMX-001
No Grade 4 cases of severe oral mucositis were observed. Grade 3 severe oral mucositis was delayed in onset and occurred in only 41.4% of patients
Rates of xerostomia were low, with long term Grade ≥ 2 events occurring in only 9.1% of subjects
At a median follow-up of 24 months, 96.6% of patients were alive without disease progression
Administration of BMX-001 showed a profound positive impact on quality of life with many measures returning to baseline by six months.
Study Background
Radiation therapy and chemotherapy induce oxidative stress that contributes to treatment-related toxicities such as oral mucositis and xerostomia which significantly impair patients’ quality of life and treatment adherence.

BMX-001 is a redox-active superoxide dismutase mimic that down-regulates oxidative stress pathways associated with radiation therapy, while stimulating repair pathways. These same impacts of BMX-001 inhibit tumor cell growth because of the unique metabolic pathways active in tumors. Preclinical studies show that BMX-001 protects normal tissues from radiation-induced injury while enhancing tumor responses to treatment.

This study represents a multi-institutional Phase I/II clinical trial of BMX-001 evaluating its safety, tolerability and efficacy in patients receiving concurrent chemoradiation for head and neck cancer.

Continued Development
"These results support the continued development of BMX-001 as a therapy to improve the efficacy and tolerability of radiation therapy in many different solid tumors," said James Crapo, MD CEO of BioMimetix. "Reducing treatment-related toxicities while preserving anti-tumor efficacy represent a unique and important step that will improve outcomes for patients with head and neck cancer."

BMX-001 is being investigated in additional clinical studies across multiple cancer types. BMX-001 is currently being evaluated in a randomized Phase II clinical trial (NRG-CC013; ClinicalTrials.gov Identifier: NCT06532279) conducted through the National Cancer Institute – supported by NRG Oncology, a Network Group in the NCI National Clinical Trials Network, to further assess its potential to reduce treatment-related toxicities in patients receiving chemoradiation for head and neck cancer.

About BMX-001
BMX-001 (MnTnBuOE-2-PyP⁵⁺) is a redox-active manganese metalloporphyrin compound that mimics the activity of superoxide dismutase enzymes and modulates oxidative stress pathways such as NFkB and HIF-1a. The compound has demonstrated potential to protect normal tissues from radiation-induced injury while maintaining or enhancing tumor response to radiation therapy with or without chemotherapy.

(Press release, BioMimetix Pharmaceutical, NOV 19, 2026, View Source [SID1234675005])

Evotec and Bristol Myers Squibb advance strategic protein degradation

On November 19, 2026 Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) reported that its strategic protein degradation partnership with Bristol Myers Squibb has received a second Investigational New Drug (IND) acceptance from the U.S. Food and Drug Administration (FDA). The first candidate produced under the partnership entered a Phase 1 clinical trial in advanced clear cell renal cell carcinoma in March 2026. The second accepted investigational drug candidate, a cereblon E3 ligase modulator (CELMoD), is expected to enter a Phase 1 clinical trial in 2027.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Initiated in 2018, the partnership combines Evotec’s high-performance multi-omics screening, AI-supported data analytics, and drug design capabilities with Bristol Myers Squibb’s industry-leading CELMoD agent library. This collaboration, expanded in 2022, continues to advance a pipeline of novel molecular glue degraders for high-value targets in oncology and beyond, translating scientific innovation into a growing therapeutic pipeline.

Dr. Joanna Holbrook, Chief Scientific Officer of Evotec, commented:

"The progression of a second molecular glue candidate to IND acceptance demonstrates the repeatability and productivity of our discovery platform. We are systematically translating complex biology into development candidates. This achievement reinforces the value of our longstanding collaboration with Bristol Myers Squibb and further strengthens our confidence in the platform’s potential to generate a growing pipeline of investigational drug candidates aimed at addressing substantial unmet medical needs."

About molecular glue degraders

Conventional small molecule therapeutics act through drug-induced interference with protein activity. This limitation to agonistic or antagonistic functions renders about 90% of proteins "undruggable". Also, conventional small molecules only work while they are actively binding to the receptor, which typically requires a treatment regimen consisting of one or even several carefully dosed medications every day.

Molecular glue degraders are compounds that induce interactions between an E3 ubiquitin ligase and a molecular target. The induced interaction results in ubiquitination and subsequent degradation of the recruited protein. By inducing neomorphic interactions between CRBN and substrate proteins, CELMoDs enable pharmacological modulation of proteins that may not be amenable to traditional inhibitor or agonist approaches, thereby expanding the potentially druggable proteome.

About Evotec’s strategic collaboration with Bristol Myers Squibb in molecular glues

In 2018, Evotec entered a long-term strategic drug discovery and development collaboration in the field of molecular glues with Celgene, now Bristol Myers Squibb. Bristol Myers Squibb is a leader in this field based on its unique library of CELMoD agents. The collaboration aims to discover and develop a leading pipeline of molecular glue degraders for a range of therapeutic indications leveraging all of Evotec’s proprietary PanOmics and PanHunter platforms as well as AI/ML-based drug discovery and development capabilities.

Evotec applies high-end proteomics and transcriptomics at industrial scale to profile and select promising drug candidates based on comprehensive cell biological profiles. Evotec’s leading PanOmics screening capabilities are delivering unmatched throughput. The selection of the most promising candidates for drug development is facilitated by Evotec’s PanOmics data analysis platform PanHunter. By integrating and analyzing these data sets, PanHunter supports the identification and advancement of the most promising CELMoDs into lead optimization.

(Press release, Evotec, NOV 19, 2026, View Source [SID1234674989])

Anixa Biosciences Announces Issuance of Canadian Patent Strengthening International Protection for its Ovarian Cancer Vaccine Technology

On November 19, 2026 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that the Canadian Intellectual Property Office (CIPO) has issued Patent Number 3,005,025 covering key aspects of Anixa’s ovarian cancer vaccine technology. The newly issued patent expands Anixa’s international intellectual property protection for a vaccine designed to harness the immune system to potentially prevent or treat ovarian cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The issued patent, exclusively licensed from Cleveland Clinic, is titled, "Ovarian Cancer Vaccines," and the co-inventors are Dr. Justin Johnson, the late Dr. Vincent Tuohy, both of Cleveland Clinic, and Dr. Suparna Mazumder, formerly of Cleveland Clinic. The patent covers methods of immunizing against the extracellular domain of anti-Müllerian hormone receptor II (AMHR2-ED), a protein domain expressed in normal ovaries prior to menopause and also aberrantly expressed in certain types of ovarian cancer.

Anixa’s ovarian cancer vaccine, being developed in collaboration with Cleveland Clinic, represents a novel approach to preventing and treating ovarian cancer, particularly among high-risk populations such as those carrying BRCA mutations or with a family history of the disease.

This "retired" protein strategy, developed at Cleveland Clinic and licensed exclusively to Anixa, is designed to train the immune system to recognize and target cells associated with ovarian cancer while seeking to avoid harm to normal tissue. The approach seeks to exploit differences in protein expression between normal tissues and cancer cells, potentially providing a new strategy for cancer treatment and prevention.

The ovarian cancer vaccine is part of Anixa’s broader cancer vaccine portfolio, which also includes its investigational breast cancer vaccine developed in collaboration with Cleveland Clinic. The breast cancer vaccine recently completed a Phase 1 clinical trial, funded by a grant from the U.S. Department of Defense, in which all primary endpoints were met. Anixa believes that targeting proteins associated with cancer may offer opportunities to develop preventive vaccines for multiple cancer types.

The Canadian patent issuance complements the Company’s existing patent protection in the United States. In July 2025, Anixa announced the issuance of U.S. Patent Number 12,357,593 covering key aspects of its ovarian cancer vaccine technology, including broad claims related to methods of eliciting an immune response targeting AMHR2-ED. Together, these patents provide protection in two important markets for Anixa’s approach to developing an ovarian cancer vaccine.

"This Canadian patent further strengthens the international patent protection around our ovarian cancer vaccine program and reinforces our intellectual property position in our AMHR2-ED-targeted immunoprevention approach," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "We believe vaccines designed to prevent cancer represent an important frontier in oncology. Our ovarian cancer vaccine is based on a differentiated scientific approach that targets a protein associated with ovarian cancer, with the long-term goal of preventing the disease before it develops. Strengthening our patent portfolio is an important part of our strategy to advance this technology and build a broader platform of cancer prevention vaccines."

(Press release, Anixa Biosciences, NOV 19, 2026, View Source [SID1234675007])

FELDAN THERAPEUTICS REPORTS PRELIMINARY PHASE 1 RESULTS FOR FLD-103 IN NODULAR BASAL CELL CARCINOMA, DEMONSTRATING A GENERALLY WELL-TOLERATED SAFETY PROFILE AND SIGNS OF CLINICAL ACTIVITY

On November 19, 2026 Feldan Therapeutics ("Feldan"), a clinical-stage biotech company specializing in the intracellular delivery of therapeutics, reported results from its Phase 1 clinical trial of FLD-103, an investigational intralesional therapy being evaluated for nodular basal cell carcinoma (nBCC). Feldan reports that FLD-103 was generally well tolerated, with exploratory assessment findings providing preliminary signs of clinical activity. The company plans to advance the program into Phase 2 to further evaluate its potential as a non-surgical treatment option for basal cell carcinoma, the most common type of skin cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The open-label study enrolled 32 participants across nine single- and multiple-ascending-dose (SAD/MAD) cohorts at eight clinical sites in the United States and Australia.

Safety and tolerability (primary objective)
The primary objective of this Phase 1 study was to evaluate the safety and tolerability of FLD-103. Preliminary data indicate that FLD-103 was generally well tolerated across all dose cohorts. The large majority of adverse events were mild to moderate in severity, were temporary, and resolved completely. The safety profile was consistent across SAD and MAD cohorts. There were no deaths and no discontinuations due to adverse events. The independent Safety Review Committee (SRC) supported continued dose escalation at each cohort review.

Preliminary signs of activity (exploratory objective)
Exploratory objectives of the study included a preliminary assessment of changes from baseline in treated lesions at excision, approximately four weeks after treatment. In this exploratory analysis, a reduction of more than 30% in tumor tissue compared with baseline was observed in 28 of 32 treated lesions (88%). Of these, 20 demonstrated tumor regression of more than 50%, including 6 lesions (19% of all treated lesions) with a complete histological response, defined as no detectable residual BCC tumor cells in the examined tissue.

These findings are preliminary, based on a small number of participants, from a study not designed or powered to assess efficacy, and subject to change following database lock and final analysis.

Next steps
Following database lock and completion of the data analyses, Feldan expects to report final results from FLD-103 Phase 1 in early 2027. The company intends to present full results at a scientific meeting and to submit them for publication in a peer-reviewed journal. Feldan plans to engage with the U.S. Food and Drug Administration (FDA) to seek feedback on the design of a proposed randomized, double-blind, vehicle-controlled Phase 2 study of FLD-103.

"Basal cell carcinoma is the most common skin cancer I treat. Many of these patients seek non-surgical alternatives," said Ashish C. Bhatia, MD, FAAD, double board-certified dermatologist and Mohs surgeon at Oak Dermatology. "While surgery remains the standard of care for most patients, there is a meaningful opportunity to expand the non-surgical treatment landscape. An intralesional approach such as FLD-103 has the potential to treat the tumor while preserving function and providing a good cosmetic outcome. Preliminary findings from the FLD-103 Phase 1 study are noteworthy and reinforce the potential of this approach. I look forward to seeing how the program evolves and its ability to contribute to the treatment landscape for basal cell carcinoma."

John Strasswimmer, MD, PhD, Director of the Clinical Trials Unit at Dermatology Associates of the Palm Beaches and Affiliate Clinical Professor of Dermatology at the FAU College of Medicine, added: "Basal cell carcinoma is the most common skin cancer, and surgery remains the mainstay of treatment for its most common subtype, nodular BCC. There is an important need to investigate additional non-surgical options for selected patients. The early Phase 1 observations with FLD-103, including its tolerability profile and histological changes seen in treated lesions, are encouraging and support further evaluation. A carefully designed Phase 2 study of Feldan’s investigational FLD-103 could help determine whether a series of injections directly into the tumor might offer a non-surgical treatment option. Establishing safety, tumor clearance and durability of response will be essential."

"Completing dosing in this Phase 1 study marks an important milestone for FLD-103, Feldan, and our proprietary Shuttle platform," said François-Thomas Michaud, CEO and co-founder of Feldan Therapeutics. "Millions of patients face surgery and facial scarring each year due to basal cell carcinoma, and we remain focused on evaluating FLD-103’s potential to offer a new treatment approach. In addition to achieving our primary safety and tolerability objectives, it is encouraging to see preliminary signs of clinical activity in the exploratory assessments, providing further rationale to advance FLD-103’s clinical development. The data generated will help inform the next stage of development and advance our plans toward a Phase 2 study. We are grateful to the patients, investigators, and teams who contributed to this study."

About Basal Cell Carcinoma and FLD-103
Basal cell carcinoma (BCC), the most common type of skin cancer, leads to 4.3 million diagnoses each year in North America. It is characterized by the development of tumors, primarily in sun-exposed areas of the skin such as the face, neck, and scalp. While the standard treatment for BCC is surgical removal or excision, non-surgical treatments are also available; however, they are not suitable for all types of BCC, often show limited efficacy, and some have been associated with adverse events. FLD-103 is an intralesional investigational treatment intended to selectively target nodular BCC cells by inhibiting the intracellular master regulator involved in the disease’s pathophysiology. With the aim of preserving surrounding healthy tissue and supporting cosmetically favorable outcomes, FLD-103 has the potential to become a non-surgical treatment, offering a new option for patients suffering from BCC.

(Press release, Feldan Therapeutics, NOV 19, 2026, View Source [SID1234674990])